Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is a phase 1/2, interventional study registered as NCT06814496 by University of Arizona, with a registry enrolment figure of 30 participants, started 2025-09-08 and due to reach its primary completion in 2030-05. Interventions recorded: Tarlatamab; Concurrent Radiation Therapy; Sequential Radiation therapy. Conditions listed: Melanoma; Medullary Thyroid Cancer; Sinonasal Undifferentiated Carcinoma; Esthesioneuroblastoma; Bladder Cancer; Testicular Cancer; Glioblastoma Multiforme; Cervical Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Non Small Cell Lung Cancer;. Primary outcome: Percentage of participants experiencing dose limiting toxicities (DLT) attributed to radiation or combination of radiation and tarlatamab.. Lung eligibility wording from the registry: "SCLC". Sites: United States. No results are recorded here; the registry entry is the source.